-DOCSTART- -X- O
Respiratory -X- _ B-Outcome
viral -X- _ I-Outcome
infections -X- _ I-Outcome
are -X- _ I-Outcome
the -X- _ I-Outcome
most -X- _ I-Outcome
important -X- _ I-Outcome
triggers -X- _ I-Outcome
of -X- _ I-Outcome
asthma -X- _ I-Outcome
exacerbations. -X- _ I-Outcome
Rhinovirus -X- _ B-Patient
( -X- _ I-Patient
RV -X- _ I-Patient
) -X- _ I-Patient
, -X- _ I-Patient
the -X- _ I-Patient
common -X- _ I-Patient
cold -X- _ I-Patient
virus -X- _ I-Patient
, -X- _ O
is -X- _ O
clearly -X- _ O
the -X- _ O
most -X- _ O
prevalent -X- _ O
pathogen -X- _ O
constantly -X- _ O
circulating -X- _ O
in -X- _ O
the -X- _ O
community. -X- _ O
This -X- _ O
virus -X- _ O
also -X- _ O
stands -X- _ O
out -X- _ O
from -X- _ O
other -X- _ O
viral -X- _ O
factors -X- _ O
due -X- _ O
to -X- _ O
its -X- _ O
large -X- _ O
diversity -X- _ O
( -X- _ O
about -X- _ O
170 -X- _ O
genotypes -X- _ O
) -X- _ O
, -X- _ O
very -X- _ O
effective -X- _ O
replication -X- _ O
, -X- _ O
a -X- _ O
tendency -X- _ O
to -X- _ O
create -X- _ O
Th2-biased -X- _ O
inflammatory -X- _ O
environment -X- _ O
and -X- _ O
association -X- _ O
with -X- _ O
specific -X- _ O
risk -X- _ O
genes -X- _ O
in -X- _ O
people -X- _ O
predisposed -X- _ O
to -X- _ O
asthma -X- _ O
development -X- _ O
( -X- _ O
CDHR3 -X- _ O
) -X- _ O
. -X- _ O
Decreased -X- _ O
interferon -X- _ O
responses -X- _ O
, -X- _ O
disrupted -X- _ O
airway -X- _ O
epithelial -X- _ O
barrier -X- _ O
, -X- _ O
environmental -X- _ O
exposures -X- _ O
( -X- _ O
including -X- _ O
biased -X- _ O
airway -X- _ O
microbiome -X- _ O
) -X- _ O
, -X- _ O
and -X- _ O
nutritional -X- _ O
deficiencies -X- _ O
( -X- _ O
low -X- _ O
in -X- _ O
vitamin -X- _ O
D -X- _ O
and -X- _ O
fish -X- _ O
oil -X- _ O
) -X- _ O
increase -X- _ O
risk -X- _ O
to -X- _ O
RV -X- _ O
and -X- _ O
other -X- _ O
virus -X- _ O
infections. -X- _ O
It -X- _ O
is -X- _ O
intensively -X- _ O
debated -X- _ O
whether -X- _ O
viral -X- _ O
illnesses -X- _ O
actually -X- _ O
cause -X- _ O
asthma. -X- _ O
Respiratory -X- _ O
syncytial -X- _ O
virus -X- _ O
( -X- _ O
RSV -X- _ O
) -X- _ O
is -X- _ O
the -X- _ O
leading -X- _ O
causative -X- _ O
agent -X- _ O
of -X- _ O
bronchiolitis -X- _ O
, -X- _ O
whereas -X- _ O
RV -X- _ O
starts -X- _ O
to -X- _ O
dominate -X- _ O
after -X- _ O
1 -X- _ O
year -X- _ O
of -X- _ O
age. -X- _ O
Breathing -X- _ B-Outcome
difficulty -X- _ I-Outcome
induced -X- _ I-Outcome
by -X- _ I-Outcome
either -X- _ I-Outcome
of -X- _ I-Outcome
these -X- _ I-Outcome
viruses -X- _ I-Outcome
is -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
later -X- _ I-Outcome
asthma -X- _ I-Outcome
, -X- _ I-Outcome
but -X- _ I-Outcome
the -X- _ I-Outcome
risk -X- _ I-Outcome
is -X- _ I-Outcome
higher -X- _ I-Outcome
for -X- _ I-Outcome
those -X- _ I-Outcome
who -X- _ I-Outcome
suffer -X- _ I-Outcome
from -X- _ I-Outcome
severe -X- _ I-Outcome
RV-induced -X- _ I-Outcome
wheezing. -X- _ I-Outcome
The -X- _ O
asthma -X- _ O
development -X- _ O
associated -X- _ O
with -X- _ O
these -X- _ O
viruses -X- _ O
has -X- _ O
unique -X- _ O
mechanisms -X- _ O
, -X- _ O
but -X- _ O
in -X- _ O
general -X- _ O
, -X- _ O
RV -X- _ B-Outcome
is -X- _ I-Outcome
a -X- _ I-Outcome
risk -X- _ I-Outcome
factor -X- _ I-Outcome
for -X- _ I-Outcome
later -X- _ I-Outcome
atopic -X- _ I-Outcome
asthma -X- _ I-Outcome
, -X- _ O
whereas -X- _ O
RSV -X- _ B-Outcome
is -X- _ I-Outcome
more -X- _ I-Outcome
likely -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
later -X- _ I-Outcome
non-atopic -X- _ I-Outcome
asthma. -X- _ I-Outcome
Treatments -X- _ O
that -X- _ O
inhibit -X- _ O
inflammation -X- _ O
( -X- _ O
corticosteroids -X- _ B-Intervention
, -X- _ I-Intervention
omalizumab -X- _ I-Intervention
) -X- _ O
effectively -X- _ B-Outcome
decrease -X- _ I-Outcome
RV-induced -X- _ I-Outcome
wheezing -X- _ I-Outcome
and -X- _ I-Outcome
asthma -X- _ I-Outcome
exacerbations. -X- _ I-Outcome
The -X- _ O
anti-RSV -X- _ O
monoclonal -X- _ O
antibody -X- _ O
, -X- _ O
palivizumab -X- _ B-Intervention
, -X- _ O
decreases -X- _ B-Outcome
the -X- _ I-Outcome
risk -X- _ I-Outcome
of -X- _ I-Outcome
severe -X- _ I-Outcome
RSV -X- _ I-Outcome
illness -X- _ I-Outcome
and -X- _ I-Outcome
subsequent -X- _ I-Outcome
recurrent -X- _ I-Outcome
wheeze. -X- _ I-Outcome
A -X- _ O
better -X- _ O
understanding -X- _ O
of -X- _ O
personal -X- _ O
and -X- _ O
environmental -X- _ O
risk -X- _ O
factors -X- _ O
and -X- _ O
inflammatory -X- _ O
mechanisms -X- _ O
leading -X- _ O
to -X- _ O
asthma -X- _ O
is -X- _ O
crucial -X- _ O
in -X- _ O
developing -X- _ O
new -X- _ O
strategies -X- _ O
for -X- _ O
the -X- _ O
prevention -X- _ O
and -X- _ O
treatment -X- _ O
of -X- _ O
asthma -X- _ O
. -X- _ O

